Mark J. Ratain to Molecular Targeted Therapy
This is a "connection" page, showing publications Mark J. Ratain has written about Molecular Targeted Therapy.
Connection Strength
1.048
-
Targeted therapies: redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol. 2014 Sep; 11(9):503-4.
Score: 0.404
-
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity? Clin Cancer Res. 2012 Aug 15; 18(16):4219-21.
Score: 0.352
-
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424.
Score: 0.129
-
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
Score: 0.082
-
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
Score: 0.081